Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04328090
Other study ID # 2020-ZX10
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 27, 2020
Est. completion date June 30, 2021

Study information

Verified date March 2022
Source China National Center for Cardiovascular Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is an open-label, two-arm, cluster-randomized, controlled trial with cardiovascular surgical teams as the unit of randomization. Eligible teams with written consent are randomized to the intervention or control arm by random number generator. Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm. Teams in the control arm will continue with usual clinical care.


Description:

The aim of the EPIC trial is to assess if a multicomponent computer-based system incorporated into the workflow can reduce days of therapy (DOT) per admission after cardiovascular surgeries in the intervention surgical teams compared with controlled surgical teams, over a one-year period. This trial is an open-label, two-arm, cluster-randomized, controlled trial with cardiovascular surgical teams as the unit of randomization. Eligible teams with written consent are randomized to the intervention or control arm by random number generator. Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm. Teams in the control arm will continue with usual clinical care. The intervention includes re-evaluation alerts and decision support for the duration of antimicrobial treatment, re-evaluation alerts and decision support for the choice of antimicrobial, and quality control audit and feedback. Nine teams per arm with an average size of 1125 admissions will be recruited. Primary outcome will be the overall systemic antibiotic use measured in DOT of systemic antibiotic use per admission. Secondary outcomes include a series of indices to evaluate antimicrobial use, microbial resistance, perioperative infection outcomes, patient safety, resource consumption and user compliance/satisfaction.


Recruitment information / eligibility

Status Completed
Enrollment 2473
Est. completion date June 30, 2021
Est. primary completion date May 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Over 18 years of age; 2. Receiving at least one open-chest cardiovascular surgery during the same admission. Exclusion Criteria: 1. Intravenous or oral antimicrobial use within two weeks before surgery; 2. Emergent/urgent surgery; 3. Admitted for isolated stenting or heart transplantation or implantation of ventricular assist device or implantation of extracorporeal membrane oxygenation; 4. Admitted for subacute bacterial endocarditis; 5. Length of ICU stay over 48 hours.

Study Design


Intervention

Other:
Computer based Antimicrobial stewardship (AMS) intervention system
Re-evaluation alerts and decision support for the duration of antimicrobial treatment. Re-evaluation alerts and decision support for the choice of antimicrobial. Quality control audit and feedback.

Locations

Country Name City State
China Fuwai Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Days of antimicrobial therapy (DOT) per admission DOT represents a specific antibiotic administered to an individual patient on a calendar day independent of dose and route. From the date of admission to the date of discharge, assessed up to 3 months.
Primary DOT per 1000 patient-days (PD) DOT per 1000 patient-days From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Drug usage (DDDs) per 100 PD Items issued × Amount of drug per item per 100 PD From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Drug usage (DDDs) per admission Items issued × Amount of drug per item per admission From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Length of therapy (LOT) per 100 PD Number of days during which antimicrobial is used per 100 PD From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Length of therapy (LOT) per admission Number of days during which antimicrobial is used per admission From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Days per treatment period overall and for specific indications treatment period: antibiotic treatment not interrupted by more than one calendar day or discharge. From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Rate of participants with clostridium difficile colitis Colitis associated with Clostridium dif?cile infection From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Incident clinical cultures with multidrug resistant organisms (MRSA, ESBL-E, CRE, VRE, or Pseudomonas aeruginosa) per 1000 PD and admission. MRSA=methicillin-resistant Staphylococcus aureus; ESBL-E=extended spectrum beta-lactamase producing Enterobacteriaceae; CRE=Carbapenem resistant Enterobacteriaceae; VRE=vancomycin-resistant enterococci. From the date of admission to the date of discharge, assessed up to 60 days.
Secondary In-hospital or 30-day surgical site infections (SSIs) Occurs within 30 days postoperatively and involves skin or subcutaneous tissue of the incision and at least one of the following: (1) purulent drainage from the incision, (2) organisms isolated from an aseptically obtained culture of fluid or tissue from the incision, (3) at least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat, and incision is deliberately opened by surgeon and is culture-positive or not cultured (a culture-negative finding does not meet this criterion), and (4) diagnosis of SSI by the surgeon or attending physician. 30 days from accomplished of the surgery.
Secondary Rate of in-hospital bloodstream infections Blood stream infection after surgery (ICD 10: A41.9) From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Rate of in-hospital pneumonia Pulmonary infection after surgery (ICD 10:J98.402) From the date of admission to the date of discharge, assessed up to 60 days.
Secondary In-hospital or 30-day mortality, postoperative mortality with in 30-day after the surgery 30 days from accomplished of the surgery or within hospital.
Secondary In-hospital or 30-day myocardial infarction (MI), postoperative and newly onset MI (in accordance with the fourth edition of MI definition) was termed type 5 MI, procedure related MI. Briefly, the criteria are as follows:
Elevation of cardiac troponin (cTn)>10 times of the 9th percentile upper reference limit with patients with normal baseline;
For patients with elevated preprocedural cTn values, elevation of cTn>10 fold increase and manifest a change from the baseline value of over 20%;
With as least one of the following:
Development of new pathological Q waves;
Imaging evidence of loss of viable myocardium that is presumed to be new and in a pattern consistent with an ischemic aetiology;
Angiographic findings consistent with a procedural flow-limiting complication.
30 days from accomplished of the surgery or within hospital.
Secondary In-hospital or 30-day stroke, postoperative and newly onset Stroke refers to newly onset stroke after surgery (ICD 10: I60.0-I60.9; I61.0-I61.9; I62.0; I62.1; I62.9; I63.0-I63.9; I64) 30 days from accomplished of the surgery or within hospital
Secondary In-hospital or 30-day acute kidney injury (AKI) , postoperative and newly onset AKI refers to newly onset AKI after surgery
Acute renal dysfunction within 48 hours (ICD 10: N17);
AKI stage I: creatinine=26.5µmol/L; creatinine over 1.5-1.9 times of baseline value; urine output<0.5ml/kg/hour for 6-12
30 days from accomplished of the surgery or within hospital
Secondary Length of hospital stay (LOS) Length of hospital stay (LOS) From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Costs of administered antimicrobials (overall and by class) per admission Costs of administered antimicrobials (overall and by class) per admission From the date of admission to the date of discharge, assessed up to 60 days.
Secondary Total costs of hospitalization Total costs of hospitalization From the date of admission to the date of discharge, assessed up to 60 days.
Secondary User satisfaction with the system Using questionnaire and an interview guide for the process evaluation of the intervention system. From the date of inclusion of the first patient to the date of discharge of the last patient, assessed up to 12 months.
Secondary User compliance with the system Ccompliance with the multicomponent intervention protocols will be assessed. This will be done by evaluating the total number of times the intervention tools fail to change the physicians' decision on antimicrobial prescription over the intervention period. From the date of inclusion of the first patient to the date of discharge of the last patient, assessed up to 12 months.
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A